Effects of transportation conditions on survival rate of umbilical cord mesenchymal stem cells

doi:10.3969/j.issn.2095-4344.2013.36.008

Abstract

Abstract:

BACKGROUND: General assessment of viability of umbilical cord mesenchymal stem cells during transport is not considered at home and abroad.
OBJECTIVE: To explore the effects of different transportation conditions such as albumin and transport time on survival rate of umbilical cord mesenchymal stem cells.
METHODS: Umbilical cord mesenchymal stem cells cultured in vitro were divided into experimental and control groups. Each of group contained 3.15×10⁹/L cells in 3 mL normal saline. The experimental group contained 1% albumin in dark environment. The control group included two subgroups: dark preservation group with the absence of albumin and light preservation group with the presence of albumin. Cell counting, trypan blue staining and cell survival rate were compared at 0, 2, 4, 8, and 24 hours.
RESULTS AND CONCLUSION: Compared with the control group, no cell loss was observed in experimental group (with the presence of albumin in the dark) and a 90% viability ratio was achieved at 8 hours. In the control group without albumin, loss rate reached 38.5% and survival rate reached 86% at 8 hours. Results revealed that 1% albumin predominantly improved cell survival rate in long-distance transport of umbilical cord mesenchymal stem cells. When transport time was more than 8 hours, cell loss rate increased and cell survival rate downregulated. Our experimental data demonstrated that umbilical cord mesenchymal stem cells preserved in normal saline consisting of 1% albumin placing in dark environment at 16 ℃ apply to clinical application criterion in 8 hours.

Key words: stem cells, umbilical cord, mesenchymal stem cells, serum albumin

CLC Number:

R394.2

Wang Da-kun, Wang Zhi-hui, Guo Hong, Zhang Le-ling. Effects of transportation conditions on survival rate of umbilical cord mesenchymal stem cells[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(36): 6430-6435.

Figures/Tables 4

References

[1] Fridenshtein A.[Stromal bone marrow cells and the hematopoietic microenvironment]. Arkh Patol.1982;44(10): 3-11.
[2] Pittenger MF, Mackay AM, Beck SC, et al.Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411): 143-147.
[3] Paolo Bianco，Pamela Gehron Robey.Marrow stromal stem cells. J Clin Invest. 2000;105(12): 1663-1668.
[4] Wakitani S, Saito T, Caplan AI. Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle Nerve.1995;18(12): 1417-1426.
[5] Woodbury D, Schwarz EJ, Prockop DJ, et al.Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res.2000;61(4): 364-370.
[6] Reyes M, Lund T, Lenvik T, et al.Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood.2001;98(9): 2615-2625.
[7] Venkataramana NK, Kumar SK, Balaraju S, et al. Open-labeled study of unilateral autologous bone-marrow- derived mesenchymal stem cell transplantation in Parkinson's disease. Transl Res.2010;155(2):62-70.
[8] Hare JM, Traverse JH, Henry TD, et al.A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol.2009; 54(24):2277-2286.
[9] Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M,et al.Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med.2007;10(4): 459-466.
[10] Matthay MA, Thompson BT, Read EJ, et al.Therapeutic potential of mesenchymal stem cells for severe acute lung injury. Chest.2010;138(4):965-972.
[11] Le Blanc K, Frassoni F, Ball L, et al.Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet.2008; 371(9624):1579-1586.
[12] Baksh D, Yao R, Tuan RS. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells. 2007;25(6):1384-1392.
[13] Yoo KH, Jang IK, Lee MW, et al.Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell Immunol.2009; 259(2): 150-156.
[14] La Rocca G, Anzalone R, Corrao S,et al.Isolation and characterization of Oct-4+/HLA-G+ mesenchymal stem cells from human umbilical cord matrix: differentiation potential and detection of new markers. Histochem Cell Biol.2009;131(2): 267-282.
[15] Jo CH, Kim OS, Park EY,et al.Fetal mesenchymal stem cells derived from human umbilical cord sustain primitive characteristics during extensive expansion. Cell Tissue Res.2008;334(3):423-433.
[16] Yoon JH, Roh EY, Shin S, JH.et al.Introducing pulsed low- intensity ultrasound to culturing human umbilical cord-derived mesenchymal stem cells. Biotechnol Lett.2009;31(3): 329-335.
[17] Kim JW, Kim SY, Park SY, et al.Mesenchymal progenitor cells in the human umbilical cord. Ann Hematol.2004;83(12): 733-738.
[18] Zhang L, Zhang HT, Hong SQ, et al.Cografted Wharton's jelly cells-derived neurospheres and BDNF promote functional recovery after rat spinal cord transection. Neurochem Res. 2009;34(11): 2030-2039.
[19] Secco M, Moreira YB, Zucconi E, et al.Gene expression profile of mesenchymal stem cells from paired umbilical cord units: cord is different from blood. Stem Cell Rev.2009;5(4): 387-401.
[20] Dominici M, Le Blanc K, Mueller I,et al.Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy.2006;8(4):315-317.
[21] Horwitz EM, Le Blanc K, Dominici M, et al.Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy. 2005;7(5):393-395.
[22] Karahuseyinoglu S, Cinar O, Kilic E, et al.Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys. Stem Cells.2007;25(2): 319-331.
[23] Wang HS, Hung SC, Peng ST, et al.Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells. 2004;22(7):1330-1337.
[24] Lu LL, Liu YJ, Yang SG, et al.Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica.2006;91(8):1017-1026.
[25] Pang KM, Sung MA, Alrash-dan MS, et al. Trans-plantation of mesenchymal stem cells from human umbilical cord versus human umbilical cord blood for peripheral nerve regenera-tion. Neural Regen Res. 2010;5(11):838-845.
[26] Hunt CJ.Cryopreservation of Human Stem Cells for Clinical Application: A Review. Transfus Med Hemother.2011;38(2): 107-123.
[27] Ball LM, Bermardo ME, Roelofs H, et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood, 2007;110(7): p. 2764-2767.
[28] Mohyeddin-Bonab M, Mohamad-Hassani MR, Alimoghaddam K, et al.Autologous in vitro expanded mesenchymal stem cell therapy for human old myocardial infarction. Arch Iran Med. 2007;10(4):467-473.
[29] Centeno CJ, Busse D, Kisiday J,et al.Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. Pain Physician.2008;11(3):343-353.
[30] Sun L, Akiyama K, Zhang H, et al.Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells.2009; 27(6):1421-1432.
[31] Wang D, Zhang F, Shen W, et al.Mesenchymal stem cell injection ameliorates the inducibility of ventricular arrhythmias after myocardial infarction in rats. Int J Cardiol.2011;152(3): 314-320.
[32] Pal R, Hanwate M, Totey SM. Effect of holding time, temperature and different parenteral solutions on viability and functionality of adult bone marrow-derived mesenchymal stem cells before transplantation. J Tissue Eng Regen Med. 2008;2(7):436-444.
[33] Cramer C, Freisinger E, Jones RK, et al.Persistent high glucose concentrations alter the regenerative potential of mesenchymal stem cells. Stem Cells Dev.2010;19(12): 1875-1884.
[34] Stolzing A, Coleman N, Scutt A.Glucose-induced replicative senescence in mesenchymal stem cells. Rejuvenation Res. 2006;9(1): p.31-35.
[35] Lo T, Ho JH, Yang MH,et al.Glucose reduction prevents replicative senescence and increases mitochondrial respiration in human mesenchymal stem cells. Cell Transplant. 2011;20(6):813-825.
[36] Grzelak A, Rychlik B, Bartosz G.Light-dependent generation of reactive oxygen species in cell culture media. Free Radic Biol Med.2001;30(12): 1418-1425.